finding,pubmed_id,finding_id
"In patients with HIV infection, pulmonary syndromes may present due to infectious causes, such as Pneumocystis jirovecii (PJ) pneumonia, Mycobacterium tuberculosis (MTB), and fungal infections, as well as noninfectious causes, such as Kaposi's sarcoma, lymphoma, and drug toxicities.",PMC2658678,PMC2658678_0
"The incidence of Kaposi's sarcoma has declined in patients treated with antiretroviral therapy (ART), but primary B-cell lymphomas elsewhere continue to occur in HIV-infected individuals.",PMC2658678,PMC2658678_1
"Patients with HIV infection may develop immune reconstitution inflammatory syndrome (IRIS) when ART is initiated, particularly in those with low CD4+ T-cell counts and high viral loads.",PMC2658678,PMC2658678_2
"Patients with HIV infection may also develop premature atherosclerosis, and clinicians should recognize ischemic heart disease and congestive heart failure as differential diagnoses when they present with pulmonary syndromes.",PMC2658678,PMC2658678_3
"Patients with HIV infection may develop a hypersensitivity syndrome to abacavir, a nucleoside reverse transcriptase inhibitor (NRTI), which can present with fever, rash, fatigue, cough, and pulmonary infiltrates, and can be fatal if rechallenged.",PMC2658678,PMC2658678_4
"Patients with HIV infection may also develop mitochondrial toxicity from nucleosides, particularly didanosine and stavudine, after long-term use of nucleoside reverse transcriptase inhibitors, and lactic acidosis may develop.",PMC2658678,PMC2658678_5
"Patients with HIV infection may develop multicentric Castleman's disease, a human herpesvirus 8 (HHV-8)– and Epstein-Barr virus (EBV)–associated lymphoproliferative disorder, which can present with pulmonary infiltrates, fever, lethargy, adenopathy, and cytopenias.",PMC2658678,PMC2658678_6
"Patients with HIV infection may also develop accelerated atherosclerosis, and clinicians should be aware of this, particularly as the population ages.",PMC2658678,PMC2658678_7
Patients with HIV infection may develop drug-induced toxicities from,PMC2658678,PMC2658678_8
